Nantahala Capital Management LLC Invests $8.97 Million in Fractyl Health, Inc. $GUTS

Nantahala Capital Management LLC bought a new stake in Fractyl Health, Inc. (NASDAQ:GUTS) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 11,289,096 shares of the company’s stock, valued at approximately $8,968,058. Nantahala Capital Management LLC owned approximately 7.09% of Fractyl Health at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Jane Street Group LLC acquired a new stake in Fractyl Health in the second quarter valued at $31,000. Jump Financial LLC acquired a new position in shares of Fractyl Health during the 4th quarter worth about $57,000. Scientech Research LLC bought a new stake in shares of Fractyl Health in the 3rd quarter valued at about $49,000. Sanctuary Advisors LLC bought a new stake in shares of Fractyl Health in the 2nd quarter valued at about $26,000. Finally, Prelude Capital Management LLC acquired a new stake in Fractyl Health in the 3rd quarter valued at about $55,000.

Insider Buying and Selling

In other news, Director Ian Sheffield purchased 35,000 shares of the company’s stock in a transaction that occurred on Wednesday, June 10th. The stock was acquired at an average cost of $0.73 per share, with a total value of $25,550.00. Following the acquisition, the director owned 35,000 shares in the company, valued at approximately $25,550. This trade represents a ? increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director William Bradley purchased 68,493 shares of the company’s stock in a transaction that occurred on Wednesday, June 10th. The shares were purchased at an average cost of $0.73 per share, with a total value of $49,999.89. Following the completion of the acquisition, the director owned 84,622 shares in the company, valued at $61,774.06. The trade was a 424.66% increase in their position. The SEC filing for this purchase provides additional information. In the last 90 days, insiders have bought 171,493 shares of company stock valued at $127,150. Corporate insiders own 8.52% of the company’s stock.

Fractyl Health Stock Performance

NASDAQ GUTS opened at $0.66 on Friday. The stock has a market cap of $104.90 million, a PE ratio of -0.75 and a beta of 2.32. The company has a debt-to-equity ratio of 1.41, a quick ratio of 3.15 and a current ratio of 3.15. The firm has a 50-day moving average of $0.75 and a 200-day moving average of $0.66. Fractyl Health, Inc. has a 52-week low of $0.38 and a 52-week high of $2.44.

Fractyl Health (NASDAQ:GUTS) last announced its quarterly earnings results on Monday, August 10th. The company reported ($0.12) EPS for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.02. On average, sell-side analysts anticipate that Fractyl Health, Inc. will post -0.53 EPS for the current year.

Analysts Set New Price Targets

GUTS has been the subject of a number of research analyst reports. Wall Street Zen cut Fractyl Health from a “hold” rating to a “sell” rating in a report on Saturday, August 15th. Craig Hallum assumed coverage on Fractyl Health in a research note on Wednesday, July 1st. They issued a “buy” rating and a $4.00 price objective on the stock. Weiss Ratings upgraded Fractyl Health from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, August 20th. Finally, HC Wainwright reiterated a “buy” rating and set a $8.00 target price on shares of Fractyl Health in a research note on Thursday, June 4th. Three equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $5.50.

About Fractyl Health

Fractyl Health, Inc is a clinical-stage medical technology company focused on the development and commercialization of minimally invasive, endoscopic therapies for metabolic diseases. Headquartered in Lexington, Massachusetts, Fractyl is advancing treatments that target the underlying physiology of conditions such as type 2 diabetes, obesity and nonalcoholic fatty liver disease (NAFLD) by modifying the duodenal mucosa to improve metabolic control.

The company’s lead product, Revita® Duodenal Mucosal Resurfacing (Revita DMR), employs a catheter-based hydrothermal ablation technique to remodel the lining of the upper small intestine.